- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | Biodesix announces one-for-twenty reverse stock split | 1 | Seeking Alpha | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 14:06 | Biodesix, Inc.: Biodesix Announces One-for-Twenty Reverse Stock Split | 62 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock... ► Artikel lesen | |
| 14:00 | BIODESIX INC - 8-K, Current Report | 2 | SEC Filings | ||
| 04.09. | Biodesix Stock Surges Over 51% Overnight After Jack Schuler's $1.5M Share Purchase Revealed | 2 | Benzinga.com | ||
| 19.08. | Biodesix, Inc.: Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics | 5 | GlobeNewswire (USA) | ||
| 07.08. | Biodesix GAAP EPS of -$0.08 misses by $0.01, revenue of $20M beats by $1.53M | 2 | Seeking Alpha | ||
| 07.08. | BIODESIX INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Biodesix, Inc.: Biodesix Announces Second Quarter 2025 Results and Highlights | 154 | GlobeNewswire (Europe) | Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance... ► Artikel lesen | |
| 07.08. | BIODESIX INC - 8-K, Current Report | 2 | SEC Filings | ||
| 24.07. | Biodesix, Inc.: Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 | 1 | GlobeNewswire (USA) | ||
| 10.06. | Biodesix, Inc.: Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs | 1 | GlobeNewswire (USA) | ||
| 04.06. | Biodesix auf der 45. jährlichen William Blair Growth Stock Konferenz: Fokus auf Lungengesundheit | 3 | Investing.com Deutsch | ||
| 30.05. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.05. | Biodesix, Inc.: Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 21.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Scotiabank cuts Biodesix stock target to $2, maintains outlook | 3 | Investing.com | ||
| 15.05. | Biodesix, Inc.: Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS | 138 | GlobeNewswire (Europe) | LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for... ► Artikel lesen | |
| 15.05. | Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 14.05. | Biodesix, Inc.: Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award | 1 | GlobeNewswire (USA) | ||
| 14.05. | Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results | 1 | Benzinga.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,015 | -39,20 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| GUARDANT HEALTH | 48,080 | -0,54 % | Guardant Health partners with PathGroup to expand blood test screening | ||
| QIAGEN | 39,000 | -1,76 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 40,140 | -13,42 % | Avidity Biosciences kündigt Aktienemission im Wert von 500 Millionen US-Dollar an | ||
| EVOTEC | 5,838 | -0,14 % | Evotec: In der Gefahrenzone | "Noch lebt die Chance" lautet eine Formulierung, wie man sie aus dem Fußballsport kennt. Nach der Interpretation des Chartbildes der Evotec-Aktie bedeutet dies: Dieser Wert kann noch die Kurve kriegen... ► Artikel lesen | |
| BIONTECH | 88,45 | +2,37 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,860 | +6,93 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
| SUMMIT THERAPEUTICS | 18,425 | +4,66 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| MAZE THERAPEUTICS | 24,200 | +50,97 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,310 | -0,40 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| TEMPUS AI | 75,50 | +12,69 % | Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move | ||
| TARSUS PHARMACEUTICALS | 51,11 | -5,96 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,820 | -0,08 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| PROKIDNEY | 2,915 | +35,90 % | ProKidney auf Morgan-Stanley-Konferenz: Strategische Einblicke in die Therapie chronischer Nierenerkrankungen | ||
| GRI BIO | 2,200 | +41,03 % | GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") |
BIODESIX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-19,21 %) liegt der Kurs bei 0,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.